Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 1, 2001 - Issue 2
Submit an article Journal homepage
72
Views
40
CrossRef citations to date
0
Altmetric
Review

General aspects of anti-angiogenesis and cancer therapy

Theresa G Zogakis Surgery Branch, National Cancer Institute, 10/2B1710 Center Drive, Bethesda, MD 20892, USA. [email protected]
&
Steven K Libutti Surgery Branch, National Cancer Institute, 10/2B1710 Center Drive, Bethesda, MD 20892, USA. [email protected]
Pages 253-275 | Published online: 23 Feb 2005

Bibliography

  • FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182–1186.
  • •• Identification of the importance of angiogenesis in cancer.
  • WEIDNER N, FOLKMAN J, POZZA F et al.: Tumorangiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.J Natl. Cancer Inst. (1992) 84(24):1875–1887.
  • WEIDNER N, CARROLL PR, FLAX J, BLUMENFELD W,FOLKMAN J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. (1993) 143(2):401–409.
  • GASPARINI G, HARRIS AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol. (1995) 13(3):765–782.
  • FOLKMAN J, INGBER D: Inhibition of angiogenesis. Semin. Cancer Biol. (1992) 3(2):89–96.
  • SENGER DR, GALLI SJ, DVORAK AM, PERRUZZI CA,HARVEY VS, DVORAK HF: Tumor cells secrete a vascular permeability factor that promotes accumula-tion of ascites fluid. Science (1983) 219(4587):983–985.
  • STRAWN LM, MCMAHON G, APP H et al.: Flk-1 as a target for tumor growth inhibition. Cancer Res. (1996) 56(15):3540–3545.
  • • Discovery of molecules targeting the Flk-1 receptor which inhibit angiogenesis.
  • ZHU Z, WITTE L: Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothe-lial growth factor. Investigational New Drugs (1999) 17:195–212.
  • LANDRISCINA M, CASSANO A, RATTO C et al.: Quantita-tive analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br. J. Cancer (1998) 78(6):765–770.
  • FUJISAKI K, MITSUYAMA K, TOYONAGA A, MATSUO K, TANIKAWA K: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am. J. Gastro-enterol. (1998) 93(2):249–252.
  • OHTA Y, ENDO Y, TANAKA M et al.: Significance ofvascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res. (1996) 2(8):1411–1416.
  • BROWN LF, TOGNAZZI K, DVORAK HF, HARRIST TJ: Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am.J. Pathol. (1996) 148(4):1065–1074.
  • TAKANAMI I, TANAKA F, HASHIZUME T, KODAIRA S: Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. (1997) 17(4A):2811–2814.
  • TAKAHASHI Y, CLEARY KR, MAI M, KITADAI Y, BUCANACD, ELLIS, LM: Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res. (1996) 2(10):1679–1684.
  • MENDEL D, LAIRD D, SMOLICH B et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Design (2000) 15(1):29–41.
  • • First selective synthetic molecule shown to inhibit the VEGF receptor.
  • FONG T, SHAWVER L, SUN L et al.: SU5416 is a potent andselective inhibitor of the vascular endothelial growth factor receptor (flk-l/kdr) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
  • ANGELOV L, SALHIA B, RONCARI L, MCMAHON G, GUHAA: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. (1999) 59:5536–5541.
  • SHAHEEN R, DAVIS D, LIU W et al.: Antiangiogenictherapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
  • ROSEN P, AMADO R, HECHT J et al.: A phase 1./11 study ofSU5416 in combination with 5fu/leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Onc. (2000) 19:5D(Abstract).
  • ERLICHMAN C, FINE S, KERR I et al.: A phase II trial of5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. (1996) 19(1):26–31.
  • YEH K, CHENG A, UN M et al A phase ii study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (hdfl) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res (1997) 17(5B):3867–3871.
  • DE GARAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer./ Clin. Oncol. (2000) 18(16):2938–2947.
  • LAIRD A, VAJKOCZY P, SHAWVER L, THURNHER A et al.:SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2000) 60:4152–4160.
  • SKOBE M, ROCKWELL P, GOLDSTEIN N, VOSSELER S, FUSENIG N: Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. (1997) 3(11):1222–1227.
  • PREWETT M, HUBER J, LI Y et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59:5209–5218.
  • •• Demonstrates that DC101 anti-VEGF receptor antibodyinhibits angiogenesis.
  • KLEMENT G, BARUCHEL S, RAK J et al.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. (2000) 105(8):R15–R24.
  • ZHU Z, ROCKWELL P, LU D et al.: Inhibition of vascularendothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. (1998) 58:3209–3214.
  • ZHU Z, LU D, KOTANIDES H et al : Inhibition of vascularendothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Letters (1999) 136:203–213.
  • ZHU Z, WITTE L, HICKLIN D et al.: Safety profile inprimates and anti-angiogenic activity in murine and canine models of a chimeric antibody directed against the vascular endothelial growth factor receptor 2. Proc. Am. Soc. Clin. Oncol. (2000) 19:1793.
  • PARRY T, CUSHMAN C, GALLEGOS A et al.: Bioactivity of anti-angiogenic ribozymes targeting fit-1 and kdr mRNA. Nucleic Acids Res. (1999) 27(13):2569–2577.
  • •• First description of the use of ribozymes targeting Flt-1 andKDR mRNA as inhibitors of angiogenesis.
  • PAVCO P, BOUHANA K, GALLEGOS A et al.: Antitumor and antirnetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Can. Res. (2000) 6:2094–2103.
  • • Use of ribozymes targeting Flt-1 and KDR mRNA as inhibi-tors of tumour growth.
  • SANDBERG J, BOUHANA K, GALLEGOS A et al.: Pharma-cokinetics of an antiangiogenic ribozyme (AngiozymeT/ in the Mouse. Antisense and Nucleic Acid Drug Devel. (1999) 9:271–277.
  • SANDBERG J, SPROUL C, BLANCHARD K et al.: Acutetoxicology and pharrnacokinetic assessment of a ribozyme (AngiozymeT/ targeting vascular endothelial growth factor receptor mrna in the cynomalogus monkey. Antisense and Nucleic Acid Drug Devel. (2000) 10:153–162.
  • PARKER V, SANDBERG J, SMITH J et al.: Phase i andpharmacokinetic studies of angiozyme, a synthetic ribozyme targeting the VEGF receptor fit-i. Proc. Am. Soc. Clin. Oncol. (2000) 19:703(Abstract).
  • KIM K, HOUCK K, WINER J, FERRARA N: The vascularendothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors (1992) 7(1):53–64.
  • BORGSTROM P, HILLAN K, SRIRAMARAO P, FERRARA N:Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. (1996) 56(17):4032–4039.
  • BORGSTROM P, BOURDON M, HILLAN K, SRIRAMARAO P, FERRARA N Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors In vivo. Prostate (1998) 35:1–10.
  • PRESTA L, CHEN H, O'CONNER S et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593–4599.
  • • Development of the first humanised anti-VEGF mAb for use in clinical trials.
  • UN Y, NGUYEN C, MENDOZA J et al.: PreclinicalpharrnacolEinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol. Exp. Ther. (1999) 288(1):371–378.
  • MORDENTI J, THOMSEN K, LICK() V, CHEN H, MENG Y,FERRARAN N: Efficacy and concentration-response of murine ant-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol. Pathol. (1999) 27(1):14–21.
  • GORDON M, TALPAZ M, MARGOLIN K et al.: Phase I trialof recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF Mab) in patients (pts) with metastatic cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:210a(Abstract).
  • BERGSLAND E, HURWITZ H, FEHRENBACHER L: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (fully) to fully alone in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:939 (Abstract).
  • DEVORE R, FEHRENBACHER L, HERBST R et al.: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (cp) to cp alone in patients with stage Hlb/IV nsck. Proc. Am. Soc. Clin. Oncol. (2000) 19:1896(Abstract).
  • SLEDGE G, MILLER K, NOVOTNY W: A phase ii trial ofsingle-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:5C(Abstract).
  • LEAVESLEY D, SCHWARTZ M, ROSENFELD M, CHERESH D: Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell Biol. (1993) 121(1):163–170.
  • BROOKS P, CLARK R, CHERESH D: Requirement of vascular integrin avI33 for angiogenesis. Science (1994) 264:569–571.
  • • Importance of avI33 in angiogenesis.
  • BROOKS P, MONTGOMERY A, ROSENFELD etai.: Integrin avI33 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157-1164. Mechanism of action of mAb to avI33 in the inhibition of angiogenesis.
  • WU H, BEUERLEIN G, NIE Y et al.: Stepwise in vitro affinity maturation of vitaxin, an avI33-specific humanized mAb. Proc. Natl. Acad. Sci. (1998) 95:6037–6042.
  • BROOKS P, STROMBLAD S, KLEMKE R, VISSCHER D, SARKAR F, CHERESH D: Anti-integrin avI33 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815–1822.
  • GUTHEIL J, CAMPBELL T, PIERCE P et al.: Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin avI33. Clinical Cancer Res. (2000) 6:3056–3061.
  • PATEL S, JENKINS J, PAPADOPOULOS E et al.: A pilot study of an angiogenesis inhibitor vitaxin in patients with advanced leiomyosarcomas (kios). Proc. Am Soc Clin Oncol (2000) 19:2202(abstract).
  • O'REILLY M, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277–285.
  • •• First description of endostatin.
  • DHANABAL M, VOLK R, RAMCHANDRAN R, SIMONS M, SUKHATME V: Cloning, expression and in vitro activity of human endostatin. Biochem. Biophys. Res. Communi-cations (1999) 258:345–352.
  • DHANABAL M, RAMCHANDRAN R, WATERMAN M et al.: Endostatin induces endothelial cell apoptosis. J. Biol. Chem. (1999) 274(17):11721–11726.
  • KIM Y, JANG J, LEE OK et al.: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metallo-proteinase 2. Cancer Res. (2000) 60:5410–5413.
  • TADDEI L,K CHIARUGI P, BROGELLI L et al.: Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem. Biophys. Res. Communications (1999) 263:340–345.
  • PERLETTI G, CONCARI P, GIARDINI R et al.: Antitumoractivity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. (2000) 60:1793–1796.
  • FELDMAN A, RESTIFO N, ALEXANDER R et al.: Antiangio-genic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. (2000) 60:1503–1506.
  • MELLIN G, KATSENSTEIN M: The saga of thalidomide. N Engl. J. Med. (1962) 264:1184–1193.
  • D'AMATO R, LOUGHNAN M, FLYNN E, FOLKMAN J: Thalidomide is and inhibitor of angiogenesis. Proc. Natl. Acad. Sci. (1994) 91:4082–4085.
  • •• First evidence of the anti-angiogenic mechanism ofthalidomide.
  • SHIMAZAWA R, MIYACHI H, TAKAYAMA H, KURODA K, KATO F, KATO M: Antiangiogenic activity of tumor necrosis factor-a production regulators derived from thalidomide. Biol. Pharm. Bull. (1999) 22:224–226.
  • CHING L, BROWNE W TCHERNEGOVASKI R, GREGORY T, BAGULEY B PALMER B: Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6 dimethybianthenone-4- acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. British J. Cancer (1998) 78:336–343.
  • MULLER G, SHIRE M, WONG L et al.: Thalidomide analogs and pde4 inhibition. Bioorg. Med. Chem. Letts. (1998) 8:2669–2674.
  • CORRAL L, HASLETT P, MULLER G et al.: Differentialcytokine modulation and t cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J. Immunol. (1999) 163:380–386.
  • MCCARTY M: Thalidomide may impede cell migrationin primates by down-regulating integrin B-chains: potential therapeutic utility in solid malignanceis, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia and osteoporosis. Med. Hypoth (1997) 49:123–131.
  • KOTOH T, DHAR D, MASUNAGA R et al.: Antiangiogenic therapy of human esophageal cancers with thalido-mide in nude mice. Surgery (1999) 125:536–544.
  • BAUER K, NIXON S, FIGG W: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. (1998) 55:1827–1834.
  • GUTMAN M, SZOLD A RAVID A, LAZAUSKAS T, MERIMSKY 0, KLAUSNER J: Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. (1996) 16:3673–3678.
  • POLITI P, REBOREDO G, LOSSO M, VUJACICH C, SCHWARTSMANN G, LEWI D: Phase I trial of thalido-mide (T) in AIDS-related Kaposi sarcoma (KS). Proc. Am. Soc. Clin. Oncol. (1998) 17:41(Abstract).
  • BAIDAS S, WINER E, FLEMING G et al.: Phase II evalua-tion of thalidomide in patients with metastatic breast cancer. j Clin. Oncol. (2000) 18:2710–2717.
  • SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565–1571.
  • FINE H, FIGG W, JAECKLE K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. (2000) 18(4):708–715.
  • LARSEN A: Suramin :an anticancer drug with uniquebiological effects. Cancer Chemother. Pharmacol. (1993) 32:96–98.
  • GAGLIARDI A, HADD H, COLLINS D: Inhibition of angiogenesis by suramin. Cancer Res. (1992) 52:5073–5075.
  • • Evidence for suramin's anti-angiogenic effect.
  • BOCCI G, ROMANI D, BENELLI U et al.: Inhibitory effectof suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother. Pharmacol. (1999)43:205–212.
  • WALTENBERGER J, ULRIDE M, HEDWIG F, HOMBACH V:Suramin is a potent inhibitor of vascular endothelial growth factor, a contribution to the molecular basis of its antiangiogenic action. j Mol. Cell. Cardiology (1996) 28:1523–1529.
  • TAKANO S, GATELY S, NEVILLE M et al.: Suramin andanticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation and induction of urokinase-type plaminogen activator. Cancer Res. (1994) 54:2654–2660.
  • PESENTI E, SOLA F, MONGELLI N, GRANDI M, SPREAFICO F: Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer (1992) 66:367–372.
  • LAROCCA R, DANESI R, COOPER M et al.: Effect on human prostate cancer cells in vitro. J. Urology (1991) 145:393–398.
  • VIGNON F, PREBOIS C, ROCHEFORT H: Inhibition ofbreast cancer growth by suramin. J. Natl. Cancer Inst. (1992) 84(1):38–42.
  • MOROCZ I, LAUBER B, SCHMITTER D, STAHEL R: In vitroeffect of suramin on lung tumour cells. Euro. J. Cancer (1993) 29A:245–247.
  • DAWN C, ZHANG Y, RAGO R, WILDING G: Efficacy ofsuramin against human prostate carcinoma DU145 xenografts in nude mice. Cancer Chemother. Pharmacol. (1999) 43:198–204.
  • SOLA F, FARAO M, MARSIGLIO A, MARIANI M, GRANDI M:Inhibition of lung and liver tumor colonies in mice pretreated with suramin. Invasion Metastasis (1993) 13(3):163–168.
  • STEIN C, LAROCCA R, THOMAS R, MCATEE N, MYERS C: Suramin: an anticancer drug with a unique mechanism of action./ Clin. Oncol. (1989) 7(4):499–508.
  • MEYERS C, COOPER M, STEIN C et al.: Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. (1992) 10(6):881–889.
  • DAWSON N, FIGG W, COOPER M et al.: Phase II trial ofsuramin, leuprolide and flutamide in previously untreated metastatic prostate cancer. J. Clin. Oncol. (1997) 15(4):1470–1477.
  • DAWSON N, FIGG W, BRAWLEY 0 et al.: Phase II study ofsuramin plus aminoglutethirnide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin. Cancer Res. (1998) 4:37–44.
  • SMALL E, MEYER M, MARSHALL M et al.: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase BI trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone/ Clin. Oncol. (2000) 18:1440–1450.
  • MIRZA M, JAKOBSEN E, PFEIFFER P, LINDEBJERG-CLASEN B, BERGH J, ROSE C: Suramin in non-small cell lung cancer and advanced breast cancer two parallel phase II studies. Acta Oncologica (1997) 36:171–174.
  • GRADISHAR W, SOFF G, LIU J et al.: A pilot trial ofsuramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology (2000) 58:324–333.
  • DREICER R, SMITH D, WILLIAMS R, SEE W: Phase II trial ofsuramin in patients with metastatic renal cell carcinoma: Investigational New Drugs (1999) 17:183–186.
  • FIRSCHING A, NICKEL P, MORA P, ALLOLIO B: Antiprolif-erative and angiostatic activity of suramin analogues. Cancer Res. (1995) 55:4957–4961.
  • FIRSCHING-HAUCK A, NICKEL P, YAHYA C et al.: Angiostatic effects of suramin analogs in vitro. Anti Cancer Drugs (2000) 11:69–77.
  • MEYERS M, GAGLIARDI A, FLATTMANN G et al.: Suraminanalogs inhibit human angiogenesis in vitro. J. Surg. Res. (2000) 91:130–134.
  • INGBER D, FUJITA T, KISHIMOTO S et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348:555–557.
  • BOND S, KLEIN S, ANDERSON G, WITTLIFF J: Interaction of angiogenesis Inhibitor TNP-470 with basic fibroblast growth factor receptors. J. Surg. Res. (2000) 92:18–22.
  • SIN N, MENG L, WANG M, WEN J, BORNMANN W, CREWSC: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine arninopeptidase, MetAP-2. Proc. Natl. Acad. Sci. (1997) 94:6099–6103.
  • LIEKENS S, VERBEKEN E, VANDEPUTTE M, DE CLERCQ E,NEYTS J: A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res. (1999) 59:2376–2383.
  • YOSHIDA T, KANEKO Y, TSUKAMOTO A et al.: Suppres-sion of hepatoma growth and angiogenesis by a fumagillin derivative TNP-470: possible involvement of nitric oxide synthase: Cancer Res. (1 9 98) 50:3751-3756.
  • KATZENSTEIN H, RADEMAKER A, SENGER C et al.: Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin. Cancer Res. (1999) 5:4273–4278.
  • O'REILLY M, BREM H, FOLKMAN J: Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J. Pediatr. Surg. (1995) 30:325–330.
  • •• Discovery of the fumagillin analogue, TNP-470.
  • TAKATSUKA S, YAMADA N, SAWADA T et al.: Contribu-tion of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int. J. Oncol. (2000) 17:253–258.
  • KANAI T, KONNO H, TANAKA T et al.: Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into the nude mice: Int. J. Cancer (1997) 71:838–841.
  • MORITA T, SHINOHARA N TOKUE A: Antitumour effect of a synthetic analogue of fumagillin on murine carcinoma. Br. J. Urol. (1994) 74:416–421.
  • YAMAOKA M, YAMAMOTO T, IKEYAMA S, SUDO K, FUJITA T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. (1993) 53(20:5233–5236.
  • YANASE T, TAMURA M, FUJITA K, KODAMA S, TANAKA K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. (1993) 53(10:2566–2570.
  • XIA J, YANG B, TANG Z, SUN F, XUE Q, GAO D: Inhibitor effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. (1997) 123(7):383–387.
  • BEECKEN W, FERNANDEZ A, PANIGRAHY D et al Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology (2000) 56(3):521–526.
  • YOSHIZAWA J, RYOJI M, TSUGINORI Y et al.: Inhibtory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma. J. Surg. Res. (2000) 93:82–87.
  • OHTA Y, WATANABE Y, TABATA T et al.: Inhibition of lymph node metastases by an anti-angiogenic agent, TNP-470. Br. J. Cancer (1997) 75(4):512–515.
  • TANAKA T, KONNO H, MATSUDA I, NAKAMURA S, BABA S Prevention of hepatic mtastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res (1995) 55(4):836–839.
  • MOLLER P, IVARSSON K, ROOS G et al.: Angiogenesis inhibitor TNP-470 augments the effect of repeated arterial ischemia on growth but does not affect take in a rat liver tumor model. Anticancer Res. (1997) 17(4A):2401–2406.
  • YAMAOKA M, YAMAMOTO T, MASAKI T, IKEYAMA S, SUDO K, FUJITA T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor 0-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res. (1 9 9 3) 53(18):4262–4267.
  • MORI S, UEDA T, KURATSU S, HOSONO N, IZAWA K UCHIDA A: Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosar-coma. Int. J. Cancer (1995) 61(1):148–152.
  • DEZUBE B, VON ROENN J, HOLDEN-WILTSE J et al.: Fumagillin analog in the treatment of kaposi's sarcoma: a phase I aids clinical trial group study. J. Clin. Oncol. (1998) 16(4):1444–1449.
  • MOORE J, DEZUBE B, GILL P, ZHOU X, ACOSTA E, SOMMADOSSI J: Phase I dose escalation pharmacoki-netics of 0-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemother. Pharmacol. (2000) 46:173–179.
  • KUDELKA A, LEVY T, VERSCHRAEGEN C: A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix: Clin. Cancer Res. (1997) 3:1501–1505.
  • SKI A, GUTTERMAN J, EBUI C et al.: Phase I trial of angiogenesis inhibitor, TNP-470 (AGM-1470) in patients with androgen independent prostate cancer. Proc. Am. Soc. Clin. Oncol. (1994) 13:(Abstract).
  • STADLER W, KUZEL T, SHAPIRO C, SOSMAN J, CLARK J, VOGELZANG N: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. (1999) 17(8):2541–2545.
  • HENDRZAK J, BRUNDA M: Antitumor and antimeta-static activity of interleukin-12. Curr. Top. Microbiol. Immunol. (1996) 213:65–83.
  • DESAI S, LIBUTTI S: Tumor angiogenesis and endothe-lial cell modulatory factors. J. Immunother. (1999) 22(3):186–211.
  • VOEST E, KENYON B, O'REILLY, TRUITT G, D'AMATO R, FOLKMAN J: Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Can. Inst. (1995) 87(8):581–589.
  • •• Demonstrates the inhibitory effect of IL-12 on angiogenesis.
  • STRIETER RM, KUNKEL S, ARENBERG D, BURDICK M, POLVERINI P: Interferon y-inducible protein 10 (IMO), a member of the CXC chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. (1995) 210:51.
  • SGADARI C, ANGIOLILLO A, TOSATO G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 87(9):3877–3882.
  • • Evidence that IL-12 might act via IP-10 to inhibit angiogenesis.
  • YAO L, SGADARI C, FURUKE K, BLOOM E, TERUYA-FELDSTEIN J, TOSATO G Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1993) 93(5):1612–1621.
  • BRUNDA M, LUISTRO L, WARRIER R et al.: Antitumor and antimetastatic activity f interleukin 12 against murine tumors. J. Exp. Med. (1993) 178:1223–1230.
  • NASTALA C, EDINGTON H, MCKINNEY T et al.: Recombi-nant IL-12 administration induces tumor regression in association with IFN-y production. J. Immunol. (1994) 153:1697–1706.
  • BOGGIO K, DICARLO E, ROVERO S et al.: Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res. (2000) 60:359–364.
  • DUDA D, SUNAMURA M, LOZONSCHI L et al.: Direct in vitro evidence and in vivo analysis of the antiangio-genesis effects of interleukin 12. Cancer Res. (2000) 60:1111–1116.
  • PORTIELJE J, KRUIT W, SCHULER M et al.: Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. (1999) 5:3983–3989.
  • MOTZER R, RAKHIT A, SCHWARTZ L et al.: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. (1998) 4:1183–1191.
  • ATKINS M, ROBERTSON M, GORDON M et al.: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignan-cies. Clin. Cancer Res. (1997) 3:409–417.
  • MURRAY G, DUNCAN M, O'NEIL P, MELVIN W, FOTHER-GILL J: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. (1996) 2(4):461–462.
  • SIER C KUBBEN F, GANESH S: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer (1996) 74(3):413–417.
  • TOKURAKU M, SATO H, MURAKAMI S, OKADA Y, WATANABE Y, SEIKI M: Activation of the precursor of gelatinase A/72 ItDa Type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int. J. Cancer (1995) 64(5):355–359.
  • ITOH T, TANIOKA M, YOSHIDA H et al.: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. (1998) 58:1048.
  • VU T, SHIPLEY J, BERGERS G et al.: MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 93:411–422.
  • BELOTTI D, PAGANONI P, GIAVAZZI R: MMP inhibitors: experimental and clinical studies. Intl. J. Biol. Markers (1999) 14(4):232–238.
  • JOHNSON M, KIM H, CHESLER L, TSAO-WU G, BOUCK N, POLVERINI P: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell Physiol. (1994) 160(1):194–202.
  • MURPHY A, UNSWORTH E, STETLER-STEVENSON W: Tissue inhibitor of metalloproteinases-2 inhibits bEGF-induced human microvascular endothelial cell proliferation. J. Cell Physiol. (1993) 157(4:351–358.
  • VALENTE P, FASSINA G, MELCHIORI A et al.: Timp-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int . J. Cancer (1998) 75:246–253.
  • WANG M, LIU Y, GREENE J, SHENG S, FUCHS A ROSEN E, SHI Y: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase. Oncogene (1997) 14(23): 1767–2774.
  • NELSON A, FINGLETON B, ROTHENBERG M, MATRISIAN L: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18(5):1135–1149.
  • KOIVUNEN E, ARAP W, VALTANEN H et al.: Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnology (1999) 17:768–774.
  • CHIRIVI R, GAROFALO A, CRIMMIN M: Inhibition of the metastatic spread and growth of b16-b16 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer (1994) 58:460–464.
  • DAVIES B, BROWN P, EAST N, CRIMMIN M, BALKWILL F: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. (1993) 53:2087–2091.
  • WATSON S, MORRIS T, ROBINSON G, CRIMMIN M, BROWN P, HARDCASTLE J: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (bb-94) in two human colon carcinoma metastasis models. Cancer Res. (1995) 55:3629–3633.
  • LOW J, JOHNSON M, BONE E, DICKSON R: The matrix metalloproteinase inhibitor batimastat (bb-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. (1996) 2:1207–1214.
  • WATSON S, MORRIS T, PARSONS S, STEELE R, BROWN P: Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br. J. Cancer (1996) 74(9):1354–1358.
  • SLEDGE G, MONA Q, GOULET R, BONE E, FIFE R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. (1995) 87(20):1546–1550.
  • TARABOLETTI G, GAROFALO A, BELOTTI D: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metallopro-teinases. J. Natl. Cancer Inst. (1995) 87(4):293–298.
  • WOJTOWICZ-PRAGA S, LOW J, MARSHALL J et al.: Phase I trial of a novel matrix metaloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Investigational New Drugs (1996) 14:193–202.
  • MACAULAY V, O& BYRNE K, SAUNDERS M: Phase I study of intrapleural batimastat (BB-94), a matrix metallo-proteinase inhibitor, in the treatment of malignant pleural effusions: Clin. Cancer Res. (1999) 5:513–520.
  • PRIMROSE J, BLEIBERG H, DANIEL F et al.: Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembry-onic antigen. Br. J. Cancer (1999) 79:509–514.
  • WOJITOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase I trial of marimastat, a novel matrix metallopro-teinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. (1998) 16(6):2150–2156.
  • TIERNEY G, GRIFFIN N, STUART R et al.: A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer: Euro. J. Cancer (1999) 35(4):563–568.
  • STEWARD W: Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol. (1999) 43:S56–S60.
  • NEMUNAITIS J, POOLE C, PRIMROSE J et al Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4:1101–1109.
  • • Multicentre study of the effect of marimastat on various cancers.
  • ROSEMURGY A, BUCKELS J, CHARNELY R: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancre-atic cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:261a.
  • NELSON A, FINGLETON B, ROTHENBERG M, MATRISIAN L: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18(5):1135–1149.
  • TARABOLETTI G, GAROFALO A, BELOTTI D et al.: Inhibi-tion of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metallo-proteinases: J. Natl. Cancer Inst. (1995) 87:293–289.
  • FLYNN C, BULL C, EBERWEIN D, MATHERNE C, HIBNER B: Anti-metastatic activity of BAY 12-9566 in human colon carcinoma HCT116 orthotopic model. Proc. Am. Assoc. Cancer Res. (1998) 39:30.
  • HIBNER B, BULL C, FLYNN C et al.: Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models. Ann. Oncol. (1998) 9:75.
  • ROWINSKY E, HUMPHREY R, HAMMOND L, AYLESWORTH C et al.: Phase land pharmacologic study of the specific matrix metalloproteinase inhibitor bay12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. (2000) 18(1):178–186.
  • YIP D, AHMAD A, KARAPETIS C, HAWKINS C, HARPER P: Matrix metalloproteinase inhibitors: applications in oncology. Investigational New Drugs (1999) 17:387–389.
  • SHALINSKY D, BREKKEN J, ZOU H et al.: Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentra-tions. Investigational New Drugs (1999) 16:303–313.
  • SHALINSKY D, BREKKEN J, ZOU H eta/.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci. (1999) 878:236–270.
  • PRICE A, QIAO S, MORRIS D et al.: Marked inhibition of tumor growth in malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. (1999) 5:845–854.
  • SHALINSKY D, BREKKEN J, ZOU H et al.: Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res. (1999) 5:1905–1917.
  • HANDE K, WILDING G, RIPPLE G et al.: A Phase I study of AG3340, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann. Oncol. (1998) 9:74.
  • D'OLIMPIO J, HANDE K, COLLIER M: Phase I study of matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (1999) 18:615(Abstract).
  • WILDING G, SMALL E, COLLIER M, DIXON M, PITHAVALA Y: A Phase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combina-tion with mitoxantrone and prednisone in ptients with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:1244(Abstract).
  • GOLUB L, RAMAMURTHY N, MCNAMARA T eta/.: Tetracy-clines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. J. Periodontal Res. (1983) 19:651–655.
  • • Discovery that tetracyclines have MMP inhibitory activity.
  • GOLUB L, GOODSON J, LEE H eta/.: Tetracyclines inhibit tissue collagenases: effects of ingested low-dose and local delivery systems. J. Periodontal Res. (1985) 56:93–97.
  • GOLUB L, RAMAMURTHY N, MCNAMARA T eta/.: Tetracy-lines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Grit. Rev. Oral Biol. Med. (1991) 2:297–321.
  • SORSA T, SALO T, KOIVUNEN E et al.: Activation of type IV procollagenases by human tumor-associated trypsin-2. J. Biol. Chem. (1997) 272(34):21067–21074.
  • LUKKONEN A, SORSA T, SALO T et al.: Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int. J. Cancer (2000) 86:577–581.
  • LEE H, GOLUB L, GAO C et al.: CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. J. Dent. Res. (MDR abstracts) (1998) 77:926.
  • SELZER M, ZHU B, BLOCK N, LOKESHWAR B et al.: CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann. NY Acad. Sci. (1999) 878:678–682.
  • LOKESHWAR B, HOUSTON-CLARK H, SELZER M, BLOCK N, GOLUB L: Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer. Adv. Dent. Res. (1998) 12(2):97–102.
  • TRACHTMAN H, FUTTERWEIT S, GREENWALD R et al.: Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. (1996) 229:243–248.
  • WASILENKO W, PALAD A, SOMERS K et al.: Effects of the calcium influx inhibitor carboxyarnido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int. J. Cancer (1996) 68:259–264.
  • ALESSANDRO R, MASIERO L, LIOTTA L, KOHN E: The role of calcium in the regulation of invasion and angiogenesis. In Vivo (1996) 10:153–160.
  • JACOBS W, MIKKELSEN T, SMITH R, NELSON K, ROSENBLUM M, KOHN E: Inhibitory effects of CAI in g,lioblastoma growth and invasion. J. Neuro-Oncol. (1997) 32:93–101.
  • LAMBERT P, SOMERS K, KOHN E, PERRY R: Antiprolifera-five and antiinvasive effects of carboxyarnido-triazole on breast cancer cell lines. Surgery (1997) 122:372–379.
  • WU Y, PALAD A, WASILENKO W et al.: Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor. Clin. Cancer Res. (1997) 3:1915–1921.
  • KOHN E, ALESSANDRO R, SPOONSTER J, WEERSTO R, LIOTTA L: Angiogenesis: role of calcium-mediated signal transduction. Proc. Nat. Acad. Sci. USA(1995) 92:1307–1311.
  • • Role for CAI in inhibiting calcium-mediated signalling events in neovascularisation.
  • GE S, REMPEL S, DIVINE G, MIKKELSEN T: Carboxyamido-triazole induces apoptosis in bovine aortic endothelial and human glioma cells. Clin. Cancer Res. (2000) 6:1248–1254.
  • KOHN E, REED E, SAROSY G et al.: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. (1996) 56:569–573.
  • BERLIN J, TUTSCH K, HUTSON P et al.: Phase I clinical and pharmacokinetic study of oraly carboxyamido-triazole, a signal transduction inhibitor. J. Clin. Oncol. (1997) 15(2):781–789.
  • KOHN E, FIGG W, SAROSY G et al.: Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacoki-netics, clinical outcome and comparison of formula-tions. J. Clin. Oncol. (1997) 15(5):1985–1993.
  • BAUER K, FIGG W, HAMILTON J et al.: A pharmacoltineti-cally guided phase ii study of carboxyarnido-triazoloe in androgen-independent prostate cancer. Clin. Cancer Res. (1999) 5:2324–2329
  • CURRAN S, MURRAY G: Matrix metalloproteinases in tumor invasion and metastases. J. Pathol. (1999) 189:300–308.
  • BROWN P: Matrix metalloproteinase inhibitors. Breast Cancer Res. & Treatment (1998) 52:125–136.

Websites

  • www.pharmacia.com/NEWS/Search.asp SU-6668 for all advanced malignancies.
  • www.imclone.com
  • www.rpi.com Ribozyme Pharmaceuticals, Inc. website.
  • http://cancemet.nci.nih.gov NIH cancer trial website.
  • http://pharmacology.tqn-com/health/pharmacology/librar y/98news/b1n0516a.htm
  • www.entremed.com/main.htm EntreMed website.
  • www.cybermedtrials.com Cybermed Trials website.
  • www.Bayerus.com/new/ 191999/09.99ud.htm1 Bayer Pharmaceutical's website, Bayer Halts Clinical Trials Evaluating MMPI.
  • www. Moffitt.usfiedu/pubs/ccj/v6n5/article3.htm LUSH R, RUDEK M, FIGG W: Review of three new agents that target angiogenesis, matrix metalloproteinases and cyclin-dependent kinases.
  • www.slip.net/--mcdavis/tnp470.htm

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.